Tilray Brands: Path To 5x Growth For TLRY Stock
1. Tilray's stock surged as Trump considers rescheduling marijuana federally. 2. Schedule III could double Tilray's revenues to $1.65 billion in three years. 3. Market could see valuation multiples expand significantly post-reclassification. 4. Risks include regulatory uncertainty and potential market saturation threats. 5. Investors face high potential upside with inherent regulatory execution risks.